

SACT Closer to Home

Professor Andrew Wardley - Andrew.Wardley@christie.nhs.uk

Clinical Director Greater Manchester Cancer SACT Pathway Board

Jonny Hirst - jonathan.hirst1@nhs.net

Pathway Manager Greater Manchester Cancer SACT Pathway Board

SACT closer to home and extending clinical trials

This poster provides an overview of the scale of SACT activity across GM, and suggests an approach for widening access to systemic therapies away from The Christie and nearer to patients homes, to enable more patients from across Greater Manchester to enjoy the same level of treatment choice as those who live near to The Christie and to offer clinical trails more widely. The solution might include offering SACT in local medical centers, hospices, community pharmacies or in people's homes. This would free up more space in hospital units to offer clinical trails more widely across GM.

Research objectives

The clinical trial research objectives from the GM Cancer Plan are:

More Patients Accessing Trials

500+ patients per year participating in early phase cancer clinical trials.
Increased access for more diverse population, particularly where research participation is low.

Discussing Trials with More Patients


Increase the proportion of patients who recall having clinical trials discussed with them following their cancer diagnosis to 40% by 2019, and reduce the variation between providers.

Groundbreaking Outreach Service

To provide more patients with access to experimental medicine.


The need for SACT to be delivered closer to home

The proportion of patients from across Greater Manchester who travel to the Christie for treatment compared to the proportion who are able to receive treatment at the hospital or location nearest to their home.



Clinical trials access

The map below shows the trail recruitment across GM in 2015/16, highlighting the need to improve access to trails.



In order to improve patients experience, alleviate capacity pressure within hospital units and offer clinical trials more widely, community based alternative sites for chemo treatment must be found, alongside establishing sites outside of the Christie that offer clinical trials.

Expected Benefits

PATIENT BENEFITS

- Improved equity of access to a greater range of treatment options and clinical trials.
- Reduced travel burden, making access to trials and treatment easier.
- Access to best possible care.
- Improved life chances.
- Improved patient experience.

SYSTEM BENEFITS

- Greater number of participants in clinical trials across all phases.
- Increase in capacity at The Christie to focus on early phase experimental medicine trials.
- Stronger relationship between partner organisations.
- Raised skills and expertise across clinical teams.